STX.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 18:07):

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs...

Stats
Dagens volum	8.52M
Gjennomsnittsvolum	7.16M
Markedsverdi	12.12M
EPS	£0 ( 2024-04-29 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.130
ATR14	£0.0400 (2.58%)

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: 0.21 (neutral)

Signal:(54.864) Neutral

Shield Therapeutics PLC Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Shield Therapeutics PLC Korrelasjon - Valuta/Råvare

0.11
( neutral )

0.71
( moderate )

0.00
( neutral )

-0.82
( strong negative )

-0.60
( weak negative )

Shield Therapeutics PLC Økonomi

Annual	2022
Omsetning:	£4.47M
Bruttogevinst:	£2.00M (44.71 %)
EPS:	£-0.170

FY	2022
Omsetning:	£4.47M
Bruttogevinst:	£2.00M (44.71 %)
EPS:	£-0.170

FY	2021
Omsetning:	£1.52M
Bruttogevinst:	£539 000 (35.48 %)
EPS:	£-0.165

FY	2020
Omsetning:	£10.39M
Bruttogevinst:	£9.03M (86.96 %)
EPS:	£-0.0200

Financial Reports:

No articles found.

Shield Therapeutics PLC

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.